Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
暂无分享,去创建一个
Y. Hiasa | A. Morishita | J. Tani | T. Ishikawa | Shinichiro Nakamura | K. Nouso | H. Toyoda | K. Tajiri | H. Iijima | H. Kosaka | S. Kakizaki | T. Kumada | M. Hirooka | A. Hiraoka | H. Ochi | Y. Koizumi | S. Fukunishi | T. Tada | S. Yasuda | A. Naganuma | K. Takaguchi | N. Shimada | M. Atsukawa | K. Kariyama | H. Ohama | N. Itokawa | T. Okubo | T. Nishimura | K. Tsuji | E. Itobayashi | A. Tsutsui | K. Kawata | T. Hatanaka | M. Imai | T. Nagano | Masaki Kaibori | C. Ogawa | T. Arai | F. Tada | Takashi Nishimura
[1] M. Kudo,et al. Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib , 2022, Cancer medicine.
[2] M. Kudo,et al. Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice , 2022, Hepatology research : the official journal of the Japan Society of Hepatology.
[3] Y. Hiasa,et al. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis , 2022, Cancer medicine.
[4] Y. Hiasa,et al. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study , 2022, Hepatology International.
[5] Y. Hiasa,et al. Neutrophil–lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis , 2022, European journal of gastroenterology & hepatology.
[6] Y. Hiasa,et al. Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis , 2022, Hepatology research : the official journal of the Japan Society of Hepatology.
[7] M. Kudo,et al. Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.
[8] H. Koga,et al. Adverse events as potential predictive factors of activity in advanced hepatocellular carcinoma patients treated with lenvatinib. , 2021, Liver international : official journal of the International Association for the Study of the Liver.
[9] M. Kudo,et al. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience , 2021, Cancer reports.
[10] A. Cucchetti,et al. Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison , 2021, Targeted Oncology.
[11] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[12] T. Kawaguchi,et al. Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study , 2020, Cancers.
[13] J. Marrero,et al. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference , 2020, Hepatology.
[14] Yulei N. Wang,et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.
[15] K. Chayama,et al. JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.
[16] D. Schadendorf,et al. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo , 2020, JAMA oncology.
[17] Y. Hiasa,et al. Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.
[18] L. Rimassa,et al. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. , 2019, Cancer treatment reviews.
[19] D. Speiser,et al. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. , 2019, JAMA Oncology.
[20] A. Alfranca,et al. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. , 2019, European journal of cancer.
[21] R. Chiari,et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis , 2018, Journal of Cancer Research and Clinical Oncology.
[22] H. Houchi,et al. Hypertension and Proteinuria as Predictive Factors of Effects of Bevacizumab on Advanced Breast Cancer in Japan. , 2018, Biological and Pharmaceutical Bulletin.
[23] M. Schlumberger,et al. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes , 2017, Endocrine.
[24] S. Nomura,et al. Retrospective analysis of bevacizumab‐induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer , 2016, Cancer medicine.
[25] H. Toyoda,et al. Impact of the branched‐chain amino acid to tyrosine ratio and branched‐chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis , 2015, Journal of gastroenterology and hepatology.
[26] H. Christofk,et al. Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy , 2015, Journal of Cell Science.
[27] W. Curran,et al. Bevacizumab‐induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab , 2015, Cancer.
[28] S. Kawasaki,et al. Evidence‐based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH‐HCC Guidelines) , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.
[29] Y. Imai,et al. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan , 2014, Liver Cancer.
[30] R. Touyz,et al. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. , 2014, The Canadian journal of cardiology.
[31] A. Danser,et al. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1 , 2013, Journal of hypertension.
[32] G. Sledge,et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. , 2013, The oncologist.
[33] Y. Kanda,et al. Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.
[34] S. Pignata,et al. Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms. , 2012, Critical reviews in oncology/hematology.
[35] E. Karapanagiotou,et al. Bevacizumab-Induced Hypertension , 2011, BioDrugs.
[36] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[37] H. Isoniemi,et al. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy , 2011, British Journal of Cancer.
[38] Xiaoyuan Chen,et al. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. , 2010, Current drug targets.
[39] R. Kurzrock,et al. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? , 2010, The oncologist.
[40] Kenneth P. Roos,et al. Autocrine VEGF Signaling Is Required for Vascular Homeostasis , 2007, Cell.
[41] J. Bruix,et al. Management of hepatocellular carcinoma , 2005, Hepatology.
[42] J. Bruix,et al. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.